Dan Ebner

Clinician scientist @MayoRadOnc, AI/ML with @MITCriticalData, heavy-ion with @QST_Japan.

[Mayo Clinic Comprehensive Cancer Center @MayoCancerCare]

A breakthrough for advanced pancreatic cancer with our investigators Drs. @MiteshBorad and @HaniBabikerMD. The findings will not only help patients but pave the way for new combination therapy and drug clinical trials. Read their perspective @BeckersHR: https://t.co/nQeX7ygPoN

[Wei Liu, PhD, DABR, FAAPM, FAIMBE @franklinliu1019]

Toward vibe medicine: A self-evolving multi-agent framework for clinic...

https://t.co/DYop8VMcYa
#vibemedicine #LLMs #AI

[Stijn Spanhove @stspanho]

🏃‍♂️ I've gamified my own run so I can race my own ghost with the Meta Ray-Ban Display.

I built a web app for the glasses, loaded a previous GPX from Strava, and dropped game mechanics on top.

Pick up coins when you keep pace, sprint zones reward extra points if you push, and a mini leaderboard on the lens shows how you're tracking against your past self in real time.

Best part: it actually works. Seeing your ghost 20 m ahead is a way stronger nudge than any number on a watch. 😅

[Nancy Lee @imrtlee]

@KaramLab @DavidSherMD @EbnerMD @xrtGenomics Working really hard to get FDA approval so all can get FMISO PET. ❤️❤️❤️

[David Sher @DavidSherMD]

75% of patients received 30 Gy with FMISO PET based de-escalation for HPV-associated OPSCC. 30 Gy.

Need the randomized data but hard to believe this won’t be the way.

Incredible!

[PDBrown @PDBrownOnc]

🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile

[Kyle 🚄 @KyleTrainEmoji]

PICARD: Data, shields up

DATA: Brilliant! Shields can reduce damage we sustain. Not immunity. Not hubris. Just prudence. It's not precaution—it's strategy.

[camera shakes]

WORF: HULL BREACHES ON NINE DECKS

DATA: Here's what happened: you told me to raise shields, and I didn't

[Stephen Chun @StephenChunMD]

A culmination of decades of work defining the role of protons for locally-advanced NSCLC. @liao_zhongxing's @UTMDAnderson long-term randomized outcomes of proton therapy for locally-advanced NSCLC just published in @ASTRO_org @IJROBP.

https://t.co/9dy27L4SWB

[Ethan Mollick @emollick]

As more people come to recognize the tells of AI, which mostly happens as you start to work with AI a lot, the scales are going to fall from their eyes and they are going to realize what some of us already see: how much of this site (and blog posts, articles, papers) are AI now.

[Daniel E Spratt @DrSpratticus]

One the amazing parts of being a chair is recruiting talent, such as @NicholasZaorsky, and fostering a culture of growth and watch the magic happen!

He was recruited during my 1st year as chair as an assistant prof. He leaves 5 yrs later as a full professor with tenure. From giving the @ASTRO_org spring refresher, coauthoring numerous guidelines, publishing up a storm, elevating our medical student clerkship, and much more.

So proud of our tremendous rockstar team. Also proud of those that have moved on to new heights including @cwspeers as Chair of Radonc at UAB, @DrMcClellandLab as Director of Cancer Inpact at OU, @KarinaNietoMD who is APD and GYN lead @MayoClinic.

Go conquer the world Nick. I will always be a fan and excited to watch your critical perspective of tech as you enter the world of carbon.

Proud of you and thanks for being part of team @RadOncUH

@angela_jia_ @lauren_henke @RaedZuhour @KashaniRojano @APrice_BeamOn @PranshuMohindra

[Dr. Nina Niu Sanford @NiuSanford]

This WSJ article getting much attention but all studies observational.

Though signal appears to be consistent & ~42 (!!) #ASCO26 abstracts also reporting association b/w GLP-1 & better cancer outcomes.

Hope for RCTs to clarify true anticancer biology vs. confounding. @OncoAlert

[Albert Attia @albertattia7]

Welcome @NicholasZaorsky!! Thrilled to have you join us! @MayoFL_RadRes

[Aadel Chaudhuri, MD PhD @aadel_chaudhuri]

Congratulations @NicholasZaorsky — Welcome to @MayoRadOnc!!

#OneMayo

[Alexander Sherry @AlexSherryMD]

1/ Tremendous thanks to the patients, coauthors and all who made the EXTEND trial possible. The primary aggregated analysis is now available online @JCO_ASCO with ctDNA correlatives presented synchronously at @ESTRO_RT #ESTRO26

[David Sher @DavidSherMD]

Absolutely terrific work by @DrSymYoung to report the long-term outcomes of our INRT experience from two prospective trials (INRT-AIR and DARTBOARD).

Short version: with long-term follow-up (median 5.2 years for INRT-AIR, 3 years for DARTBOARD), we've seen zero solitary elective nodal recurrences.

Longer version: ESTRO has highlighted novel approaches to managing the elective neck in HNSCC, and I believe the future will be very different than the present. Current ENI fields deliver the majority of the integral dose to patients and contribute substantially to critical structures (swallowing and xerostomia OARs). Minimizing ENI dose and volume may meaningfully improve the short- and especially long-term tolerance of radiotherapy.

A few more thoughts on our INRT paradigm below:

[OncoAlert @OncoAlert]

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨
De-intensification of postoperative radiotherapy in HNSCC by omitting contralateral elective neck irradiation– long term outcomes of the DIREKHT trial Presented by Charlotte Frei 🇩🇪
#RadOnc ☢️

The DIREKHT trial is a prospective multicentre phase II trial investigating de-intensified risk-adapted radiation in patients with newly diagnosed, non-metastatic HNSCC after surgery. A total of 140 patients were included in the analysis. After five years, overall locoregional recurrence rate was 6.0% (95% CI [1.9; 9.9]). Cumulative incidence of locoregional recurrence was 3.0% (95%-CI [0.1; 5.8]). Details on recurrence patterns and dysphagia rates are presented at ESTRO 2026.

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[Department of War 🇺🇸 @DeptofWar]

https://t.co/rzCVvUU3mu

[Mayo Clinic Radiation Oncology @MayoRadOnc]

Wow! Truly amazing!

[The Lead CNN @TheLeadCNN]

Two incredible breakthroughs in early cancer detection made possible by A.I.

[Aadel Chaudhuri, MD PhD @aadel_chaudhuri]

What a day it has been!!!

@AaronNewmanLab and I started this journey years ago back when we were both junior faculty. A difficult question — Can we perform liquid biopsy of the tumor microenvironment?

Spoiler alert. We finally did it! In @Nature & on @CNN today w/ @jaketapper!!